A phase 3 study (NCT04822181), which enrolled 1200 patients with biopsy-proven MASH and fibrosis, is currently ongoing to assess the benefit of OW subcutaneous semaglutide 2 mg in this setting 93
*Eligible patients without diabetes lost an average of 21% of their body weight (-48 lbs) in a 72-week clinical trial evaluating 15 mg tirzepatide, when paired with diet and exercise
Who should not use semaglutide, Ozempic, or Wegovy
These cases were usually linked to dehydration, vomiting, or diarrhea common side effects of Semaglutide that can reduce fluid levels in the body
Evaluation of out-of-pocket costs and treatment intensification with an SGLT2 inhibitor or GLP-1 receptor agonist in patients with type 2 diabetes and cardiovascular disease
(Source: KFF, January 2026) Even Where Covered, Utilization Controls Limit Access When state Medicaid programs do cover GLP-1s, coverage is typically subject to prior authorization and other utilization controls that further restrict access in practice
